Prevention Strategies

P15.01
Men Who Have Sex with Men (MSM) from Buenos Aires, Argentina: A Suitable Group for HIV Clinical Trials

M Pando, M Weissenbacher, R Marone, SM Montano, A Carballo-Dieguez, H Salomón, MM Avila

P15.02
Circumcision and HIV Acquisition Risk Among Men Who Have Sex with Men (MSM) in Buenos Aires, Argentina

M Pando, R Marone, I Balan, C Dolezal, V Barreda, A Carballo-Dieguez, MM Avila

P15.03
Community Awareness About AIDS Vaccine in Georgia

N Gulua, O Gerzmava, A Lochoshvili, I Norakidze, N Zakareishvili

P15.04
Griffithsin, Cyanovirin-N and Scytovirin Inhibit HIV-1 Binding and Transfer via the DC-SIGN Receptor

KB Alexandre, ES Gray, H Mufhandu, PL Moore, J McMahon, E Chakauya, B O'Keefe, R Chikwamba, L Morris

P15.05
Women Fisher Folk: Recruitment, Retention and Participation in HIV Prevention Research

A Ssetaala, A Nanvubya, J Mpendo, G Asiki, J Miiro, L Nielsen, J Seeley, P Kaleebu, A Kamali

P15.06
Prevention of HIV-1 Sexual Transmission Using Novel Small-Molecule CCR5 Antagonists Formulated into Temperature-Sensitive Acidic Microbicide Gel

Y Kang, L Chen, X Ding, W Li, C Lau, X Lu, Z Tan, L Liu, Z Wu, Z Chen

P15.07
Recruitment and Retention of HIV Serodiscordant Couples in a Pilot Daily and Intermittent Pre-Exposure Prophylaxis Study in Masaka, Uganda

FM Kibengo, E Ruzagira, A Bwanika, U Bahemuka, D Katende, A Abaasa, F Priddy, A Kamali

P15.08
Project VOGUE: HIV Vaccine Education in an Underserved Racial/Ethnic MSM Population

CA Bunce, SD Fields, S Wallace, D Humes, MC Keefer

P15.09
The Renewed Canadian HIV Vaccine Initiative

N Varughese, P Milsom, L Jonsdottir, S Sternthal

P15.10
Evaluating Predictors of HIV Infection Among MSM in Nigeria Towards Participation in HIV Prevention Vaccine Trial

A Adeyemi, K Oyediran, O Fakunle, K Issa, A Azeez

P15.11
Attitudes and Intent to Use PrEP Among Current Phase II Preventive HIV-1 Vaccine Trial Participants

T Madenwald, J Fuchs, M Sobieszczyk, S Karuna, A Sherwat, B Koblin, G Broder, N Eaton, M Andrasik, S Hammer,  Division of AIDS (DAIDS)HIV Vaccine Trials Network

P15.12 LB
Ring Formulated NNRTI 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide (CSIC) Showed No Toxicity in Rhesus monkeys and Retained Anti-Viral Activity

P Gupta, P Marx, J Moss, A Smith, D Ratner, M Hunter, P Tarwater, L Rohan, AM Cole, MA Parniak

P15.13 LB
Knowledge of HIV/AIDS Transmission, Prevention, Treatment and Sexual Behaviour among PLWHA in Eastern Uganda

J Abisa